{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:02:38Z","timestamp":1771434158774,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review highlights recent studies that investigate the metabolic reprogramming that occurs in specific types of bone metastatic cancers, including different types of breast cancer, prostate cancer and multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Metastatic cancer cells use altered metabolic pathways to adapt in alternate environments. Cancer cells that home towards the bone are able to manipulate their metabolism to survive in the hypoxic microenvironment, shifting between oxidative phosphorylation and glycolysis, whilst also exploiting neighbouring cells within the bone to provide energy and protect against chemotherapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Targeting the altered metabolic pathways in cancer cells could be used to improve treatments, reduce tumour burden and prevent the destruction of the bone that occurs in tumour-induced bone disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11914-026-00956-3","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T03:02:17Z","timestamp":1771210937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolism in Tumour-Induced Bone Disease"],"prefix":"10.1007","volume":"24","author":[{"given":"Renee T.","family":"Ormsby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1257-5659","authenticated-orcid":false,"given":"Claire M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"1","key":"956_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"8","key":"956_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"S8","key":"956_CR3","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","volume":"80","author":"GR Mundy","year":"1997","unstructured":"Mundy GR. Mechanisms of bone metastasis. Cancer. 1997;80(S8):1546\u201356.","journal-title":"Cancer"},{"issue":"19","key":"956_CR4","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1111\/febs.14090","volume":"284","author":"M Sciacovelli","year":"2017","unstructured":"Sciacovelli M, Frezza C. Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. FEBS J. 2017;284(19):3132\u201344.","journal-title":"FEBS J"},{"issue":"3421","key":"956_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"133","author":"S Paget","year":"1889","unstructured":"Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;133(3421):571\u20133.","journal-title":"Lancet"},{"issue":"9","key":"956_CR6","first-page":"19","volume":"1","author":"W Lin","year":"2017","unstructured":"Lin W, Xu L, Zwingenberger S, Gibon E, Goodman SB, Li G. Mesenchymal stem cells homing to improve bone healing. J Orthop Transl. 2017;1(9):19\u201327.","journal-title":"J Orthop Transl"},{"issue":"2","key":"956_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/mt.2011.259","volume":"20","author":"S Ohkouchi","year":"2012","unstructured":"Ohkouchi S, Block GJ, Katsha AM, Kanehira M, Ebina M, Kikuchi T, et al. Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the warburg effect by secreting STC1. Mol Ther. 2012;20(2):417\u201323.","journal-title":"Mol Ther"},{"issue":"1","key":"956_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943-017-0597-8","volume":"16","author":"SM Ridge","year":"2017","unstructured":"Ridge SM, Sullivan FJ, Glynn SA. Mesenchymal stem cells: key players in cancer progression. Mol Cancer. 2017;16(1):31.","journal-title":"Mol Cancer"},{"issue":"3","key":"956_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41556-020-0477-0","volume":"22","author":"RT Davis","year":"2020","unstructured":"Davis RT, Blake K, Ma D, Gabra MBI, Hernandez GA, Phung AT, et al. Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. Nat Cell Biol. 2020;22(3):310\u201320.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"956_CR10","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-22-0451","volume":"21","author":"JM Buschhaus","year":"2023","unstructured":"Buschhaus JM, Rajendran S, Chen S, Wharram BL, Bevoor AS, Cutter AC, et al. Bone marrow mesenchymal stem cells induce metabolic plasticity in estrogen receptor-positive breast cancer. Mol Cancer Res. 2023;21(5):458.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"956_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2023.101669","volume":"18","author":"HA Tirado","year":"2023","unstructured":"Tirado HA, Balasundaram N, Laaouimir L, Erdem A, van Gastel N. Metabolic crosstalk between stromal and malignant cells in the bone marrow niche. Bone Rep. 2023;18(1):101669.","journal-title":"Bone Rep"},{"issue":"5","key":"956_CR12","volume":"1880","author":"L Jin","year":"2025","unstructured":"Jin L, Shao Z, Ye Z, Li B. Osteoblasts in bone metastasis: key players in the tumor microenvironment and therapeutic targets. Biochimica et Biophysica Acta (BBA). 2025;1880(5):189435.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"2","key":"956_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1359\/JBMR.041109","volume":"20","author":"Y Sun","year":"2005","unstructured":"Sun Y, Schneider A, Jung Y, Wang J, Dai J, Wang J, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)\/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo*. J Bone Miner Res. 2005;20(2):318\u201329.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"956_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf9096","volume":"8","author":"J Whitburn","year":"2022","unstructured":"Whitburn J, Rao SR, Morris EV, Tabata S, Hirayama A, Soga T, et al. Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival. Sci Adv. 2022;8(8):eabf9096.","journal-title":"Sci Adv"},{"issue":"9","key":"956_CR15","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1158\/0008-5472.CAN-18-0773","volume":"79","author":"CR Marlein","year":"2019","unstructured":"Marlein CR, Piddock RE, Mistry JJ, Zaitseva L, Hellmich C, Horton RH, et al. CD38-driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma. Can Res. 2019;79(9):2285\u201397.","journal-title":"Can Res"},{"issue":"14","key":"956_CR16","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.3390\/cancers13143461","volume":"13","author":"Z Matula","year":"2021","unstructured":"Matula Z, Mikala G, Luk\u00e1csi S, Matk\u00f3 J, Kov\u00e1cs T, Monostori \u00c9, et al. Stromal cells serve drug resistance for multiple myeloma via mitochondrial transfer: a study on primary myeloma and stromal cells. Cancers (Basel). 2021;13(14):3461.","journal-title":"Cancers (Basel)"},{"issue":"21","key":"956_CR17","volume":"40","author":"X Wei","year":"2023","unstructured":"Wei X, Zhang Y, Wang Z, He Y, Ju S, Fu J. Bone marrow adipocytes is a new player in supporting myeloma cells proliferation and survival in myeloma microenvironment. Transl Oncol. 2023;40(21):101856.","journal-title":"Transl Oncol"},{"issue":"14","key":"956_CR18","first-page":"90","volume":"7","author":"EV Morris","year":"2016","unstructured":"Morris EV, Edwards CM. Bone marrow adipose tissue: a new player in cancer metastasis to bone. Front Endocrinol (Lausanne). 2016;7(14):90.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"956_CR19","first-page":"1768","volume":"130","author":"H Fairfield","year":"2017","unstructured":"Fairfield H, Harris EJ, Falank C, Reagan M. Myeloma-associated adipocytes exhibit reduced adipogenic gene expression and delipidation. Blood. 2017;130(8):1768.","journal-title":"Blood"},{"issue":"6","key":"956_CR20","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1182\/blood.2021013832","volume":"139","author":"C Panaroni","year":"2022","unstructured":"Panaroni C, Fulzele K, Mori T, Siu KT, Onyewadume C, Maebius A, et al. Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. Blood. 2022;139(6):876\u201388.","journal-title":"Blood"},{"issue":"494","key":"956_CR21","doi-asserted-by":"publisher","first-page":"eaau9087","DOI":"10.1126\/scitranslmed.aau9087","volume":"11","author":"H Liu","year":"2019","unstructured":"Liu H, He J, Koh SP, Zhong Y, Liu Z, Wang Z, et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med. 2019;11(494):eaau9087.","journal-title":"Sci Transl Med"},{"issue":"16","key":"956_CR22","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s12672-025-02682-1","volume":"20","author":"W Tie","year":"2025","unstructured":"Tie W, Ma T, Liu J, Yi Z, Xiong H, Bai J, et al. Visfatin promotes multiple myeloma cell proliferation and inhibits apoptosis by inducing IL-6 production via NF-\u03baB pathways. Discov Oncol. 2025;20(16):826.","journal-title":"Discov Oncol"},{"issue":"3","key":"956_CR23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1158\/0008-5472.CAN-20-1088","volume":"81","author":"H Fairfield","year":"2021","unstructured":"Fairfield H, Dudakovic A, Khatib CM, Farrell M, Costa S, Falank C, et al. Myeloma-modified adipocytes exhibit metabolic dysfunction and a senescence-associated secretory phenotype. Cancer Res. 2021;81(3):634\u201347.","journal-title":"Cancer Res"},{"issue":"11","key":"956_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2021.119101","volume":"1868","author":"MK Herroon","year":"2021","unstructured":"Herroon MK, Mecca S, Haimbaugh A, Garmo LC, Rajagurubandara E, Todi SV, et al. Adipocyte-driven unfolded protein response is a shared transcriptomic signature of metastatic prostate carcinoma cells. Biochim Biophys Acta Mol Cell Res. 2021;1868(11):119101.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"956_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.886305","volume":"10","author":"S Russo","year":"2022","unstructured":"Russo S, di Scotto CarloGianfrancesco FF. The osteoclast traces the route to bone tumors and metastases. Front Cell Dev Biol. 2022;10:886305.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"956_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1158\/0008-5472.CAN-23-1443","volume":"84","author":"H Fan","year":"2024","unstructured":"Fan H, Xu Z, Yao K, Zheng B, Zhang Y, Wang X, et al. Osteoclast cancer cell metabolic cross-talk confers PARP inhibitor resistance in bone metastatic breast cancer. Cancer Res. 2024;84(3):449\u201367.","journal-title":"Cancer Res"},{"issue":"1","key":"956_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0740-2","volume":"18","author":"KM Bussard","year":"2016","unstructured":"Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016;18(1):84.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"956_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12108-6","volume":"10","author":"R Romero-Moreno","year":"2019","unstructured":"Romero-Moreno R, Curtis KJ, Coughlin TR, Miranda-Vergara MC, Dutta S, Natarajan A, et al. The CXCL5\/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis. Nat Commun. 2019;10(1):4404.","journal-title":"Nat Commun"},{"issue":"11","key":"956_CR29","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/s41416-020-01040-y","volume":"123","author":"Y Hu","year":"2020","unstructured":"Hu Y, Xu W, Zeng H, He Z, Lu X, Zuo D, et al. OXPHOS-dependent metabolic reprogramming prompts metastatic potential of breast cancer cells under osteogenic differentiation. Br J Cancer. 2020;123(11):1644\u201355.","journal-title":"Br J Cancer"},{"issue":"1","key":"956_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40170-023-00303-5","volume":"11","author":"MB Jekabsons","year":"2023","unstructured":"Jekabsons MB, Merrell M, Skubiz AG, Thornton N, Milasta S, Green D, et al. Breast cancer cells that preferentially metastasize to lung or bone are more glycolytic, synthesize serine at greater rates, and consume less ATP and NADPH than parent MDA-MB-231 cells. Cancer Metab. 2023;11(1):4.","journal-title":"Cancer Metab"},{"issue":"40","key":"956_CR31","doi-asserted-by":"publisher","first-page":"64854","DOI":"10.18632\/oncotarget.11712","volume":"7","author":"JD Diedrich","year":"2016","unstructured":"Diedrich JD, Rajagurubandara E, Herroon MK, Mahapatra G, H\u00fcttemann M, Podgorski I. Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1\u03b1 activation. Oncotarget. 2016;7(40):64854\u201377.","journal-title":"Oncotarget"},{"issue":"1","key":"956_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1158\/1541-7786.MCR-22-0250","volume":"21","author":"F Mossa","year":"2023","unstructured":"Mossa F, Robesti D, Sumankalai R, Corey E, Titus M, Kang Y, et al. Subtype and site specific-induced metabolic vulnerabilities in prostate cancer. Mol Cancer Res. 2023;21(1):51\u201361.","journal-title":"Mol Cancer Res"},{"key":"956_CR33","doi-asserted-by":"crossref","unstructured":"G\u00e1mez B, Whipp D, Rao S, Morris EV, Park YE, Kaya Z, et al. High cholesterol increases myeloma tumour burden and promotes resistance to bortezomib [Internet]. bioRxiv; 2025 [cited 2025 Sept 8]. p. 2025.01.21.633916. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2025.01.21.633916v1","DOI":"10.1101\/2025.01.21.633916"},{"issue":"1","key":"956_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07625-w","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lan T, Zhou C, Zhang Q, Liu P. LRP8-dependent cholesterol metabolism modulates mTORC1 signaling and apoptotic pathways in multiple myeloma. Cell Death Dis. 2025;16(1):263.","journal-title":"Cell Death Dis"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-026-00956-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-026-00956-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-026-00956-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:05:36Z","timestamp":1771430736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-026-00956-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["956"],"URL":"https:\/\/doi.org\/10.1007\/s11914-026-00956-3","relation":{},"ISSN":["1544-2241"],"issn-type":[{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}